Education
About Us
Working with TipRanks
Follow Us
LENZ Therapeutics (LENZ)
NASDAQ:LENZ
LENZ Stock Chart & Stats
Day’s Range― - ―
52-Week Range$14.42 - $38.93
Previous CloseN/A
Volume24.39K
Average Volume (3M)290.02K
Market Cap
$788.01M
Enterprise Value$585.95M
Total Cash (Recent Filing)$19.82M
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)―
Beta0.57
Next Earnings
May 07, 2025EPS Estimate
-0.52Last Dividend Ex-Date
Mar 22, 2024Dividend YieldN/A
Share Statistics
EPS (TTM)-4.76
Shares Outstanding27,543,120
10 Day Avg. Volume276,206
30 Day Avg. Volume290,022
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)-20.10
P/FCF Ratio0.00
Enterprise Value/Market Cap0.74
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-243.44
Enterprise Value/Ebitda-10.01
Forecast
1Y Price Target
$49.00Price Target Upside71.27% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering8
---
LENZ Therapeutics News
PremiumCompany Announcements
LENZ Therapeutics Hosts Commercial Day for LNZ100
PremiumCompany Announcements
Lenz Therapeutics’ Earnings Call Highlights Positive Outlook
---
Bulls Say, Bears Say
Bulls Say
Clinical TrialsThe Phase 3 CLARITY program achieved primary and key secondary endpoints with statistically significant ≥3-line BCVA near vision improvement without losing 1-line or more from distance visual acuity.
Market PotentialThe company has proactively built its supply chain and has begun commercial-scale manufacturing of bulk product.
Product Launch StrategyLenz plans to use targeted advertising on streaming platforms and social media, unlike previous unsuccessful campaigns focused on linear TV.
Bears Say
Approval UncertaintyNDA review of LNZ100 continues as planned with no known or anticipated impacts from recent FDA disruptions.
FinancialsThe company ended the quarter with $209M in cash, which management believes should be enough to fund operations to post-launch positive operating cash flow.
---
Ownership Overview
16.32% Insiders
5.92% Mutual Funds
0.18% Other Institutional Investors
70.19% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
LENZ FAQ
What was LENZ Therapeutics’s price range in the past 12 months?
LENZ Therapeutics lowest stock price was $14.42 and its highest was $38.93 in the past 12 months.
What is LENZ Therapeutics’s market cap?
LENZ Therapeutics’s market cap is $788.01M.
When is LENZ Therapeutics’s upcoming earnings report date?
LENZ Therapeutics’s upcoming earnings report date is May 07, 2025 which is in 11 days.
How were LENZ Therapeutics’s earnings last quarter?
LENZ Therapeutics released its earnings results on Mar 19, 2025. The company reported -$0.46 earnings per share for the quarter, missing the consensus estimate of -$0.41 by -$0.05.
Is LENZ Therapeutics overvalued?
According to Wall Street analysts LENZ Therapeutics’s price is currently Undervalued.
Does LENZ Therapeutics pay dividends?
LENZ Therapeutics pays a Notavailable dividend of $1.029 which represents an annual dividend yield of N/A. See more information on LENZ Therapeutics dividends here
What is LENZ Therapeutics’s EPS estimate?
LENZ Therapeutics’s EPS estimate is -0.52.
How many shares outstanding does LENZ Therapeutics have?
LENZ Therapeutics has 27,543,120 shares outstanding.
What happened to LENZ Therapeutics’s price movement after its last earnings report?
LENZ Therapeutics reported an EPS of -$0.46 in its last earnings report, missing expectations of -$0.41. Following the earnings report the stock price went up 3.056%.
Which hedge fund is a major shareholder of LENZ Therapeutics?
Currently, no hedge funds are holding shares in LENZ
---
LENZ Therapeutics Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$49.00 (71.27% Upside)
$49.00 (71.27% Upside)
Blogger Sentiment
Bullish
LENZ Sentiment 100%
Sector Average 70%
Sector Average 70%
Hedge Fund Trend
Increased
By 9.0 Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Negative
Last 7 Days ▲ 2.2%
Last 30 Days ▲ 6.9%
Last 30 Days ▲ 6.9%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
80.39%
12-Months-Change
Fundamentals
Return on Equity
-25.68%
Trailing 12-Months
Asset Growth
14.25%
Trailing 12-Months
Company Description
LENZ Therapeutics
LENZ Therapeutics (LENZ) is a biopharmaceutical company focused on developing innovative treatments for eye diseases. The company operates in the healthcare sector, specifically targeting ophthalmology, with a primary emphasis on developing therapies for presbyopia and other vision-related disorders. LENZ leverages cutting-edge science and technology to create novel therapeutics that address unmet medical needs in the field of eye care.
---
LENZ Stock 12 Month Forecast
Average Price Target
$49.00
▲(71.27% Upside)
Technical Analysis
Prothena
―
Rocket Pharmaceuticals
―
Replimune Group
―
Immunome
―
Bicara Therapeutics Inc.
―
Best Analysts Covering LENZ
1 Year
1 Year Success Rate
4/8 ratings generated profit
1 Year Average Return
+5.41%
reiterated a buy rating 12 days ago
Copying Marc Goodman's trades and holding each position for 1 Year would result in 50.00% of your transactions generating a profit, with an average return of +5.41% per trade.
---